{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:56Z","timestamp":1786119236884,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1097\/cad.0b013e32803d36e6","type":"journal-article","created":{"date-parts":[[2007,8,2]],"date-time":"2007-08-02T03:01:26Z","timestamp":1186023686000},"page":"697-702","source":"Crossref","is-referenced-by-count":11,"title":["A pilot study of bendamustine in advanced bile duct cancer"],"prefix":"10.1097","volume":"18","author":[{"given":"Konrad","family":"Schoppmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"M\u00f6ssner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Caca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210203","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/gut.48.6.816","article-title":"Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968\u20131998","volume":"48","author":"Taylor-Robinson","year":"2001","journal-title":"Gut"},{"key":"R2-10-20210203","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"R3-10-20210203","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.bjc.6603127","article-title":"Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971\u20132001","volume":"94","author":"West","year":"2006","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"R5-10-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2","article-title":"Liver, gallbladder, extrahepatic bile ducts, and pancreas","volume":"75","author":"Carriaga","year":"1995","journal-title":"Cancer"},{"key":"R6-10-20210203","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-199610000-00005","article-title":"Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors","volume":"224","author":"Nakeeb","year":"1996","journal-title":"Ann Surg"},{"key":"R7-10-20210203","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.sla.0000217639.10331.47","article-title":"Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma \u2013 palliative photodynamic therapy plus stenting is comparable to R1\/R2 resection","volume":"244","author":"Witzigmann","year":"2006","journal-title":"Ann Surg"},{"key":"R9-10-20210203","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00000658-199912000-00010","article-title":"Extended resections for hilar cholangiocarcinoma","volume":"230","author":"Neuhaus","year":"1999","journal-title":"Ann Surg"},{"key":"R10-10-20210203","first-page":"597","article-title":"Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation","volume":"115","author":"Nordback","year":"1994","journal-title":"Surgery"},{"key":"R11-10-20210203","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(94)90455-3","article-title":"Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction","volume":"344","author":"Smith","year":"1994","journal-title":"Lancet"},{"key":"R12-10-20210203","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.gastro.2003.07.015","article-title":"Succesful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study","volume":"125","author":"Ortner","year":"2003","journal-title":"Gastroenterology"},{"key":"R13-10-20210203","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1572-0241.2005.00318.x","article-title":"Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy","volume":"100","author":"Zoepf","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R14-10-20210203","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.510310205","article-title":"Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival","volume":"31","author":"Berr","year":"2000","journal-title":"Hepatology"},{"key":"R15-10-20210203","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0016-5107(03)70021-2","article-title":"Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma","volume":"57","author":"Dumoulin","year":"2003","journal-title":"Gastrointest Endosc"},{"key":"R16-10-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0016-5107(04)01288-X","article-title":"Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study","volume":"60","author":"Wiedmann","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"R17-10-20210203","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00268-002-6434-1","article-title":"Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma","volume":"27","author":"Gerhards","year":"2003","journal-title":"World J Surg"},{"issue":"4","key":"R18-10-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/annonc\/10.suppl_4.S215","article-title":"Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma","volume":"10","author":"GonzalezGonzalez","year":"1999","journal-title":"Ann Oncol"},{"key":"R19-10-20210203","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0360-3016(95)02132-9","article-title":"The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and\/or external beam radiotherapy","volume":"34","author":"Kamada","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-10-20210203","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/bjs.1800821122","article-title":"Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy","volume":"82","author":"Kuvshinoff","year":"1995","journal-title":"Br J Surg"},{"key":"R21-10-20210203","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"R22-10-20210203","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjc.6602576","article-title":"Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer","volume":"92","author":"Rao","year":"2005","journal-title":"Br J Cancer"},{"key":"R23-10-20210203","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andre","year":"2004","journal-title":"Ann Oncol"},{"key":"R24-10-20210203","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","article-title":"Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial","volume":"23","author":"Knox","year":"2005","journal-title":"J Clin Oncol"},{"key":"R25-10-20210203","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/annonc\/mdh096","article-title":"Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial","volume":"15","author":"Kornek","year":"2004","journal-title":"Ann Oncol"},{"key":"R26-10-20210203","doi-asserted-by":"crossref","first-page":"A4091","DOI":"10.1200\/jco.2004.22.90140.4091","article-title":"A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas","volume":"23","author":"Nehls","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R27-10-20210203","first-page":"A1095","article-title":"Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II GOCCHI study 2000\u20132013","volume":"22","author":"Reyes-Vidal","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R28-10-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0005-2787(72)90282-1","article-title":"Investigation of cross-link formation in DNA by the alkylating cytostatika IMET 3106, 3393, and 3943","volume":"287","author":"Hartmann","year":"1972","journal-title":"Biochim Biophys Acta"},{"key":"R29-10-20210203","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anticancer Drugs"},{"key":"R30-10-20210203","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","article-title":"High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas","volume":"128","author":"Bremer","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"R31-10-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO\u266f 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"R32-10-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","article-title":"Bendamustine montherapy in advanced and refractory chronic lymphocytic leukemia","volume":"127","author":"Kath","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"R33-10-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","article-title":"Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)","volume":"132","author":"Ponisch","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"R34-10-20210203","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.cad.0000175587.31940.19","article-title":"Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC","volume":"16","author":"Von Minckwitz","year":"2005","journal-title":"Anticancer Drugs"},{"key":"R35-10-20210203","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/annonc\/mdf189","article-title":"Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"13","author":"Weidmann","year":"2002","journal-title":"Ann Oncol"},{"key":"R37-10-20210203","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1124\/dmd.105.003624","article-title":"Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma","volume":"33","author":"Teichert","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"R38-10-20210203","article-title":"UICC: TNM classification of malignant tumours","author":"Sobin","year":"2002"},{"key":"R39-10-20210203","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0016-5107(98)70218-4","article-title":"Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage","volume":"47","author":"Chang","year":"1998","journal-title":"Gastrointest Endosc"},{"key":"R40-10-20210203","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1067\/mge.2001.113381","article-title":"Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study","volume":"53","author":"De Palma","year":"2001","journal-title":"Gastrointest Endosc"},{"key":"R41-10-20210203","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s00330-004-2327-z","article-title":"Cross-sectional imaging of biliary tumors: current clinical status and future developments","volume":"14","author":"Zech","year":"2004","journal-title":"Eur Radiol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32803d36e6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:46Z","timestamp":1786039426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200707000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32803d36e6","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}